Study on GTAEXS617 for Adults with Advanced Solid Tumors

Inclusion Criteria

• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of more than 3 months.
• Have one of the following confirmed advanced solid tumors: head and neck cancer, pancreatic cancer, non-small cell lung cancer, hormone receptor-positive and HER2-negative breast cancer that has worsened after previous treatment, or certain types of ovarian, peritoneal, or fallopian tube cancers that are resistant to platinum-based treatments.
• The cancer must be advanced, recurrent, or metastatic, meaning it cannot be cured with surgery or radiation.
• Have good blood, liver, and kidney function.
• Have tumors that can be biopsied, except for bone metastases.

Exclusion Criteria

• Have an active and significant infection.
• Have severe nausea, vomiting, or digestive issues that affect drug absorption.
• Have cancer that has spread to the brain or spinal cord and is causing symptoms.
• Have another active or previous cancer.
• Have had an organ or stem-cell transplant.
• Have moderate or severe heart disease.
• Have received cancer treatment within 28 days or 5 half-lives before starting the study drug.
• Have taken certain medications that affect how the body processes drugs within 14 days or 5 half-lives before starting the study drug.
• Have unresolved serious side effects from previous cancer treatments.
• Have had major surgery less than 28 days before starting the study drug.